Baxter International Inc

More Details of Baxter International Inc Company

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

Company Info

Company codeBAX

Company nameBaxter International Inc

IPO dateMay 15, 1961

Founded at1931

CEOMr. D. Brent Shafer

Number of employees38000

Security typeOrdinary Share

Fiscal year-endMay 15

AddressOne Baxter Parkway

CityDEERFIELD

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code60015

Phone12249482000

Websitehttps://www.baxter.com/

Company codeBAX

IPO dateMay 15, 1961

Founded at1931

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Heather Knight

Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies

177.32K

+11.79%

Dr. Jeanne K. Mason, Ph.D.

Chief Human Resources Officer, Executive Vice President

141.67K

+7.47%

Mr. Alok Sonig

Executive Vice President, Group President - Pharmaceuticals

130.30K

+15.20%

Mr. David S. Rosenbloom

Executive Vice President, General Counsel

118.15K

+10.70%

Dr. Stephen N. (Steve) Oesterle, M.D.

Independent Director

28.52K

+2.77%

Ms. Catherine R. (Cathy) Smith

Independent Director

23.05K

+2.74%

Ms. Patricia B. Morrison

Independent Director

15.76K

-25.89%

Mr. Stephen H. (Steve) Rusckowski

Independent Director

9.27K

+2.46%

Mr. Jeffrey A. (Jay) Craig

Independent Director

3.47K

--

Ms. Nancy M. Schlichting

Lead Independent Director

787.00

-88.29%

Name

Name/Position

Position

Shareholding

Change

Ms. Heather Knight

Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies

177.32K

+11.79%

Dr. Jeanne K. Mason, Ph.D.

Chief Human Resources Officer, Executive Vice President

141.67K

+7.47%

Mr. Alok Sonig

Executive Vice President, Group President - Pharmaceuticals

130.30K

+15.20%

Mr. David S. Rosenbloom

Executive Vice President, General Counsel

118.15K

+10.70%

Dr. Stephen N. (Steve) Oesterle, M.D.

Independent Director

28.52K

+2.77%

Ms. Catherine R. (Cathy) Smith

Independent Director

23.05K

+2.74%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Infusion Therapies and Technologies

4.10B

38.58%

Care and Connectivity Solutions

1.81B

17.06%

Injectables and Anesthesia

1.37B

12.91%

Front Line Care

1.14B

10.69%

Advanced Surgery

1.10B

10.38%

Other

1.10B

10.39%

By RegionUSD

Name

Revenue

Proportion

United States

5.85B

55.00%

International

4.79B

45.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Infusion Therapies and Technologies

4.10B

38.58%

Care and Connectivity Solutions

1.81B

17.06%

Injectables and Anesthesia

1.37B

12.91%

Front Line Care

1.14B

10.69%

Advanced Surgery

1.10B

10.38%

Other

1.10B

10.39%

Shareholder

Update time: 14 hours ago

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.80%

Dodge & Cox

10.06%

Pzena Investment Management, LLC

6.56%

BlackRock Institutional Trust Company, N.A.

5.76%

State Street Global Advisors (US)

4.25%

Other

61.58%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.80%

Dodge & Cox

10.06%

Pzena Investment Management, LLC

6.56%

BlackRock Institutional Trust Company, N.A.

5.76%

State Street Global Advisors (US)

4.25%

Other

61.58%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

53.40%

Investment Advisor

32.35%

Research Firm

2.70%

Hedge Fund

2.37%

Pension Fund

2.23%

Insurance Company

1.44%

Bank and Trust

1.13%

Sovereign Wealth Fund

1.00%

Individual Investor

0.36%

Other

3.01%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1902

499.25M

97.33%

-40.58M

2024Q4

1984

501.11M

97.98%

-41.68M

2024Q3

2005

485.40M

95.14%

-42.32M

2024Q2

2042

472.72M

92.77%

-47.98M

2024Q1

2091

469.13M

92.11%

-57.76M

2023Q4

2137

471.69M

92.98%

-44.04M

2023Q3

2123

465.39M

91.91%

-35.52M

2023Q2

2140

458.55M

90.66%

-30.65M

2023Q1

2123

459.27M

90.86%

-22.24M

2022Q4

2132

456.58M

90.57%

-21.28M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

60.53M

11.8%

+468.84K

+0.78%

Dec 31, 2024

Dodge & Cox

51.58M

10.06%

+1.20M

+2.39%

Feb 28, 2025

Pzena Investment Management, LLC

33.64M

6.56%

+1.42M

+4.39%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

29.53M

5.76%

-652.43K

-2.16%

Dec 31, 2024

State Street Global Advisors (US)

21.79M

4.25%

+12.21K

+0.06%

Dec 31, 2024

BlackRock Financial Management, Inc.

17.57M

3.43%

+1.23M

+7.54%

Dec 31, 2024

T. Rowe Price Associates, Inc.

15.25M

2.97%

+1.13M

+8.03%

Dec 31, 2024

Geode Capital Management, L.L.C.

12.45M

2.43%

+290.28K

+2.39%

Dec 31, 2024

Harris Associates L.P.

8.46M

1.65%

-1.31M

-13.43%

Dec 31, 2024

Columbia Threadneedle Investments (US)

7.28M

1.42%

-2.29M

-23.93%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Parnassus Value Select ETF

5.07%

Cullen Enhanced Equity Income ETF

3.53%

iShares Large Cap Value Active ETF

2.45%

Global X S&P 500 Quality Dividend ETF

2%

iShares U.S. Medical Devices ETF

1.92%

Invesco S&P 500 Equal Weight Health Care ETF

1.76%

SPDR S&P Health Care Equipment ETF

1.52%

First Trust Indxx Medical Devices ETF

1.27%

ROBO Global Healthcare Technology & Innovation ETF

0.98%

Humankind US Stock ETF

0.85%

Parnassus Value Select ETF

Proportion5.07%

Cullen Enhanced Equity Income ETF

Proportion3.53%

iShares Large Cap Value Active ETF

Proportion2.45%

Global X S&P 500 Quality Dividend ETF

Proportion2%

iShares U.S. Medical Devices ETF

Proportion1.92%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.76%

SPDR S&P Health Care Equipment ETF

Proportion1.52%

First Trust Indxx Medical Devices ETF

Proportion1.27%

ROBO Global Healthcare Technology & Innovation ETF

Proportion0.98%

Humankind US Stock ETF

Proportion0.85%

Dividend

A total of 2.75B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 11, 2025

BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option

Feb 28, 2025

Apr 01, 2025

Feb 28, 2025

Nov 11, 2024

BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option

Nov 29, 2024

Jan 02, 2025

Nov 29, 2024

Jul 16, 2024

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option

Aug 30, 2024

Oct 01, 2024

Aug 30, 2024

May 07, 2024

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option

May 31, 2024

Jul 01, 2024

May 31, 2024

Feb 12, 2024

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option

Mar 01, 2024

Apr 01, 2024

Feb 29, 2024

Nov 14, 2023

BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option

Dec 01, 2023

Jan 02, 2024

Nov 30, 2023

Jul 18, 2023

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option

Sep 01, 2023

Oct 02, 2023

Aug 31, 2023

May 01, 2023

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 03, 2023 going ex on Jun 01, 2023

Jun 02, 2023

Jul 03, 2023

Jun 01, 2023

Feb 14, 2023

BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 03, 2023 going ex on Feb 23, 2023 with reinvestment option

Feb 24, 2023

Apr 03, 2023

Feb 23, 2023

Nov 15, 2022

BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 03, 2023 going ex on Dec 01, 2022

Dec 02, 2022

Jan 03, 2023

Dec 01, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

31.335USD

Baxter International Inc

31.335

Overview

Company